SRTD raises €31.5M seed round to develop cell-selective RNA therapies
Germany-based biotech company SRTD Biotech has closed a €31.5 million seed funding round. At the heart of its approach is an RNA technology designed to address a fundamental challenge facing many RNA-based therapies: How can the activity of a therapeutic molecule be restricted to specific cells without unnecessarily harming healthy tissue?

